Inpatient cost analysis for treatment of myasthenia gravis

Abstract

There was a dramatic and disproportionate rise in the number of MG discharges, most likely because of changes in practice patterns. Muscle Nerve 56: 1114-1118, 2017.

Incidence, mortality, and economic burden of myasthenia gravis in China: A nationwide population-based study

“…Increasing effort in healthcare outreach have resulted in an increasing level of insurance coverage. Correspondingly, the hospitalization cost was lower than previously reported [23] .…”

Economic Costs of Myasthenia Gravis: A Systematic Review

“…Of these, 274 were duplicates, 543 were excluded following title and abstract screening, and 31 were selected for full-text review. Finally, 16 articles [9][10][11][12][13][14][15][16][17][18][19][20][21][22][23][24] were considered for data extraction and synthesis. Summary details of the included publications are presented in Table 1.…”

“…In total, six of 16 (38%) of identified articles estimated the direct medical costs of MG [11,12,14,17,19,20], seven of 16 (44%) estimated cost per hospitalization [14,16,18,[21][22][23][24], three of 16 (19%) estimated costs of IVIG and PLEX as a treatment for MG crisis/exacerbation [10,13,15], two of 16 (13%) estimated indirect costs [19,20], and one of 16 (6%) estimated costs of myasthenic crisis [9], cost per MG outpatient care service [14], and total cost of illness [19], respectively (Table 1). Schepelmann et al [19] also estimated informal care costs of MG in Germany, accounted for as an indirect cost of illness.…”

“…The lowest estimate was derived from a sample of 936 Thai patients hospitalized for MG [22], and the highest for 994 US patients hospitalized for MG requiring continuous mechanical ventilation [21]. In relation to all US hospital admission that calendar year, Omorodion et al [18] estimated the mean per-patient added cost per hospitalization for MG exacerbation in the US in 2013 at $59,340 ($98,800 vs. $39,460). Looking into results from reported subgroup analyses, Omorodion et al [18] found costs per hospitalization to be higher for males compared with females hospitalized for MG exacerbation ($119,100 vs. $97,330) and in the West of the US compared with the Midwest ($55,850 vs. $34,560), whereas Souayah et al [21] reported higher costs for urban non-teaching compared with teaching hospitals ($165,150 vs. $104,980), and both recognized that the mean per-patient cost per hospitalization varied markedly by age (Table 2).…”

Accuracy of patient-reported data for an online patient registry of autoimmune myasthenia gravis and Lambert-Eaton myasthenic syndrome

“…A remarkable finding is that the rate of admissions due to MG have not diminished, but increased over time, whereas hospital admission for other autoimmune diseases, such as multiple sclerosis (MS) has decreased [35][36][37][38] , despite an increasing prevalence of MS. The increasing available treatment options for MS compared to MG have been suggested as a possible explanation for this difference [35] .…”